These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23905680)

  • 21. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
    Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
    J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
    Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
    J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
    Li Y; Shin D; Kwon SH
    FEBS J; 2013 Feb; 280(3):775-93. PubMed ID: 23181831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
    Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
    J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
    Tan S; He F; Kong T; Wu J; Liu Z
    Bioorg Med Chem; 2017 Aug; 25(15):4123-4132. PubMed ID: 28629630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors.
    Lee HY; Yang CR; Lai MJ; Huang HL; Hsieh YL; Liu YM; Yeh TK; Li YH; Mehndiratta S; Teng CM; Liou JP
    Chembiochem; 2013 Jul; 14(10):1248-54. PubMed ID: 23788254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
    Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
    Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
    Marek L; Hamacher A; Hansen FK; Kuna K; Gohlke H; Kassack MU; Kurz T
    J Med Chem; 2013 Jan; 56(2):427-36. PubMed ID: 23252603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
    Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
    Thakur A; Tawa GJ; Henderson MJ; Danchik C; Liu S; Shah P; Wang AQ; Dunn G; Kabir M; Padilha EC; Xu X; Simeonov A; Kharbanda S; Stone R; Grewal G
    J Med Chem; 2020 Apr; 63(8):4256-4292. PubMed ID: 32212730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease.
    Liang T; Liu S; Dang B; Luan X; Guo Y; Steimbach RR; Hu J; Lu L; Yue P; Wang R; Zheng M; Gao J; Yin X; Chen X
    Eur J Med Chem; 2024 Sep; 275():116624. PubMed ID: 38925015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6.
    Zilberman Y; Ballestrem C; Carramusa L; Mazitschek R; Khochbin S; Bershadsky A
    J Cell Sci; 2009 Oct; 122(Pt 19):3531-41. PubMed ID: 19737819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors selective for HDAC6 in enzymes and cells.
    Gupta PK; Reid RC; Liu L; Lucke AJ; Broomfield SA; Andrews MR; Sweet MJ; Fairlie DP
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7067-70. PubMed ID: 20947351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.